Tiazofurin (2-Beta-D-ribofuranosyl-4-thiazolecarboxamide) | |
---|---|
Trade Name | |
Orphan Indication | Chronic myeloid leukemia |
USA Market Approval | USA |
USA Designation Date | 2000-12-27 00:00:00 |
Sponsor | Valeant Pharmaceuticals North America;3300 Hyland Avenue;Costa Mesa, California, 92626 |
Related Access Program
Pusan National University Hospital – Chronic Myeloid Leukemia
University of California, San Francisco – Chronic Myeloid Leukemia
Emory University – Chronic Myeloid Leukemia
Pusan National University Hospital – Chronic myeloid leukemia
University of California, San Francisco – Chronic myeloid leukemia
Pfizer – Chronic myeloid leukemia
Emory University – Chronic myeloid leukemia